Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET

Vaxart (OTCQX: VXRT) will host a virtual stockholder fireside chat on Friday, August 7, 2026, at 4:30 p.m. ET / 1:30 p.m. PT as part of its regular FAQ-focused series for investors.

Rhea-AI Summary

Vaxart (OTCQX: VXRT) will host a virtual stockholder fireside chat on Friday, August 7, 2026, at 4:30 p.m. ET / 1:30 p.m. PT as part of its regular FAQ-focused series for investors.

The company plans to report second quarter 2026 financial results for the period ended June 30, 2026, after market close on Thursday, August 6, 2026. The live webcast and replay will be available via www.vaxart.com, and investors can submit written questions in advance by email to IR@vaxart.com or through the webcast portal. Vaxart is a clinical-stage biotechnology company developing oral pill vaccines for coronavirus, norovirus, influenza and a therapeutic HPV program using its proprietary recombinant vaccine delivery platform.

Argus Jul 30 session

+9.18% close to close Open Argus

Details

Market reaction after 2Q26 earnings report: VXRT +9.18% in the Jul 30 session

In the Jul 30 session, VXRT gained 9.18%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +9.2% in the session following this news. The 5.26% reaction to Vaxart’s cooperation...

Analysis

The stock moved +9.2% in the session following this news. The 5.26% reaction to Vaxart’s cooperation agreement provides a historical comparison for this scheduled investor event. The active S-3 shelf allows offerings of up to $300,000,000, a financing risk to monitor alongside the results.

Key Figures

Fireside chat date: August 7, 2026 Fireside chat time: 4:30 p.m. ET / 1:30 p.m. PT Reporting period: Second quarter 2026 +2 more

Fireside chat date

August 7, 2026

Stockholder fireside chat

Fireside chat time

4:30 p.m. ET / 1:30 p.m. PT

Stockholder fireside chat

Reporting period

Second quarter 2026

Financial results to be reported after market close

Quarter-end date

June 30, 2026

Second quarter 2026

Results announcement date

August 6, 2026

Second quarter 2026 financial results

Historical Context

5 past events · Latest: Jul 21

5 events

1. Jul 21

   Biotech conference

   24h Move

   +0.6%

   Management participation in a virtual one-on-one biotechnology conference

2. Jul 17

   Annual meeting results

   24h Move

   -2.9%

   Stockholders rejected named executive officer compensation in an advisory vote

3. Jul 6

   Clinical safety data

   24h Move

   -10.8%

   Twelve-month safety data reported from the Phase 2b sentinel cohort

4. Jul 1

   Governance agreement

   24h Move

   +5.3%

   Cooperation agreement resolved the proxy contest and added governance enhancements

5. Jun 26

   Proxy solicitation

   24h Move

   +6.4%

   Company urged shareholders to support all six director nominees

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

recombinant vaccines, adenovirus, tlr3 agonists, immune-oncology

4 terms

recombinant vaccines medical

"developing a range of oral recombinant vaccines based on its proprietary delivery platform"

Vaccines made using recombinant technology are created by inserting genetic instructions for a specific part of a pathogen (like a protein) into harmless cells or microbes, which then produce that piece for use as the vaccine ingredient. For investors, they matter because this approach can speed development, allow precise targeting and scalable manufacturing—similar to ordering a single, repeatable part from a factory instead of growing whole organisms—affecting costs, timelines and supply reliability.

adenovirus medical

"oral vaccination using adenovirus and TLR3 agonists"

Adenovirus is a family of viruses that commonly cause mild respiratory or eye infections and is also used in medicine as a delivery vehicle to carry genes or vaccine material into cells. Investors monitor developments involving adenoviruses because safety signals, clinical trial results, or regulatory decisions tied to therapies and vaccines that use them can quickly change a company's perceived risks and potential market value—like whether a delivery truck arrives intact determines whether goods reach buyers.

tlr3 agonists medical

"oral vaccination using adenovirus and TLR3 agonists"

TLR3 agonists are drugs or molecules that activate Toll-like receptor 3, an immune system sensor that detects double-stranded RNA and triggers an antiviral and inflammatory response. Think of TLR3 as a smoke detector and an agonist as the signal that sets off the alarm; activating this pathway can boost vaccine responses, stimulate cancer-fighting immune cells, or enhance antiviral defenses. They matter to investors because successful TLR3 agonists can become components of vaccines, cancer immunotherapies, or antiviral treatments, influencing clinical trial value, regulatory review, manufacturing needs, and market opportunity.

immune-oncology medical

"Vaxart’s first immune-oncology indication"

Immune-oncology is a branch of medicine that develops treatments which help a patient’s own immune system find and fight cancer, rather than attacking tumors directly with chemicals or radiation. For investors, it matters because these therapies can create large new markets or transform care pathways when successful, but they also carry high clinical trial, regulatory and commercialization risk—think of them as high-reward, high-uncertainty innovations like breakthrough technologies in other industries.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company to report second quarter 2026 financial results on August 6

SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of the Company’s senior management team will participate in a virtual fireside chat on Friday, August 7, 2026, at 4:30 p.m. ET / 1:30 p.m. PT as part of its regular series to answer frequently asked questions from its stockholders. The Company plans to report financial results for the second quarter ended June 30, 2026, after the market close on Thursday, August 6, 2026.

The live fireside chat can be accessed by clicking here or on the Company’s website at www.vaxart.com.

Investors may submit written questions in advance of the conference call to ir@vaxart.com or through the webcast portal.

A replay of the fireside chat webcast will be available on the Company’s website at www.vaxart.com following the conclusion of the event.

About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contact
Vaxart Media and Investor Relations:
FINN Partners
IR@vaxart.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Vaxart (OTCQX: VXRT) hosting its stockholder fireside chat on August 7, 2026?

Vaxart will host its virtual stockholder fireside chat on Friday, August 7, 2026, at 4:30 p.m. ET / 1:30 p.m. PT. According to Vaxart, this event is part of its regular series addressing frequently asked stockholder questions.

How can investors access Vaxart's August 7, 2026 VXRT stockholder fireside chat webcast?

Investors can access the live fireside chat webcast by visiting www.vaxart.com and clicking the webcast link. According to Vaxart, a replay of the fireside chat will also be available on the company’s website following the conclusion of the event.

When will Vaxart (VXRT) report its second quarter 2026 financial results?

Vaxart plans to report its second quarter 2026 financial results after market close on Thursday, August 6, 2026. According to Vaxart, these results will cover the quarter ended June 30, 2026, ahead of the August 7 stockholder fireside chat.

Can Vaxart stockholders submit questions for the August 7, 2026 VXRT fireside chat?

Yes, stockholders can submit written questions in advance of the fireside chat. According to Vaxart, questions may be sent to IR@vaxart.com or submitted through the webcast portal before or during the virtual event.

What type of vaccines is Vaxart (VXRT) developing with its oral pill platform?

Vaxart is developing oral recombinant vaccines delivered as pills using its proprietary platform. According to Vaxart, current programs target coronavirus, norovirus, influenza, and a therapeutic HPV vaccine, which is described as the company’s first immune-oncology indication.

How are Vaxart’s VXRT oral vaccines designed to be stored and administered?

Vaxart’s vaccines are designed to be administered as pills that do not require refrigeration. According to Vaxart, this pill format aims to simplify shipping and storage and eliminates the risk of needle-stick injury associated with injectable vaccines.